Top performer TCG secures two commitments from Rhode Island

The Column Group is close to reaching its fundraising target of $600m apiece for its early-stage life science Fund V and later-stage Opportunity Fund III.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.